Guttiga Halue

Guttiga Halue

Auto-generated profile, based on publicly available information

Guttiga Halue

Department of Medicine Phayao Hospital Phayao Thailand

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2023 in Nephrology
Verified
Journal Article
Closed access
GHGuttiga Halue
Guttiga Halue
HTHuttaporn Tharapanich
Huttaporn Tharapanich
JPJeerath Phannajit
Jeerath Phannajit
TKTALERNGSAK KANJANABUCH
TALERNGSAK KANJANABUCH
ABAthiphat Banjongjit
Athiphat Banjongjit
TCThailand PDOPPS Steering Committee
Thailand PDOPPS Steering Committee

1 November 2019 in Journal of Infection
Verified
Journal Article
Open access
GLGeoffroy Liegeon
Geoffroy Liegeon
LHLinda Harrison
Linda Harrison
ANAnouar Nechba
Anouar Nechba
GHGuttiga Halue
Guttiga Halue
SBSukit Banchongkit
Sukit Banchongkit
GJGonzague Jourdain
Gonzague Jourdain
The risk of kidney dysfunction on the WHO recommended first line regimens containing tenofovir disoproxil fumarate (TDF) without protease inhibitors (PI) remains unclear in Asian patients, especially those with low body weight. Using data collected in a multicenter clinical trial in Thailand and proportional hazard regression models, we compared the risk of a >25% estimated glomerular filtration rate (eGFR) reduction in HIV naïve patients initiating TDF or zidovudine (AZT) containing non-PI regimen. Of 640 patients included in the analysis, 461 (72%) received a TDF-containing regimen for a median 6.7 years and 179 (28%) an AZT-containing regimen for 6.5 years. The risk of a >25% eGFR reduction was not associated with treatment (HR 1.11, 95% CI 0.84-1.47, P = 0.46). In multivariate analysis, the risk of >25% eGFR reduction form baseline was associated with body weight at baseline (HR 2.12, 95% CI 1.48-3.02 for 60 kg, P < 0.001) and hypertension (HR 4.03, 95% CI 2.0-8.0, P < 0.001). The effect of baseline weight on >25% eGFR reduction did not significantly vary with treatment (P = 0.27). The risk of eGFR reduction was not higher on TDF- versus AZT-based non-PI regimens. Although the risk of eGFR reduction was greater for patients of lower body weight, this risk was not significantly increased by TDF.